Insulet Co. (NASDAQ:PODD) Shares Acquired by Baillie Gifford & Co.

Baillie Gifford & Co. raised its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 20.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,275,701 shares of the medical instruments supplier's stock after purchasing an additional 389,639 shares during the period. Baillie Gifford & Co. owned 3.25% of Insulet worth $529,669,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Blue Trust Inc. lifted its holdings in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock valued at $30,000 after acquiring an additional 58 shares during the last quarter. Venturi Wealth Management LLC raised its position in Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock worth $36,000 after purchasing an additional 133 shares during the period. International Assets Investment Management LLC purchased a new stake in Insulet in the 2nd quarter worth about $32,000. UMB Bank n.a. raised its position in Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier's stock worth $37,000 after purchasing an additional 81 shares during the period. Finally, CVA Family Office LLC raised its position in Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier's stock worth $50,000 after purchasing an additional 145 shares during the period.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. UBS Group raised their target price on shares of Insulet from $211.00 to $223.00 and gave the stock a "neutral" rating in a research report on Friday, August 9th. Morgan Stanley raised their target price on shares of Insulet from $234.00 to $317.00 and gave the stock an "overweight" rating in a research report on Monday. Canaccord Genuity Group increased their price objective on shares of Insulet from $236.00 to $269.00 and gave the company a "buy" rating in a research note on Wednesday, September 25th. Citigroup increased their price objective on shares of Insulet from $250.00 to $275.00 and gave the company a "buy" rating in a research note on Tuesday, October 1st. Finally, Sanford C. Bernstein initiated coverage on shares of Insulet in a research note on Wednesday, November 6th. They set an "outperform" rating and a $300.00 price objective on the stock. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $253.27.

Insulet Price Performance

Shares of PODD stock traded down $3.15 during mid-day trading on Tuesday, hitting $272.55. 313,243 shares of the stock were exchanged, compared to its average volume of 780,087. Insulet Co. has a 52-week low of $156.00 and a 52-week high of $279.40. The company has a market cap of $19.11 billion, a PE ratio of 47.21, a price-to-earnings-growth ratio of 5.00 and a beta of 1.22. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. The firm has a fifty day moving average of $233.46 and a 200 day moving average of $205.26.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.